These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8349998)

  • 1. Aspirin and coronary artery diseases.
    Jauhari J
    J Indian Med Assoc; 1993 Mar; 91(3):50-1. PubMed ID: 8349998
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of aspirin in ischemic heart disease].
    Frishman W; Horwitz S
    Arch Inst Cardiol Mex; 1977; 47(2):129-31. PubMed ID: 901049
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acetylsalicylic acid in the prevention and therapy of thromboembolic diseases. Principles of practical use].
    Breddin K
    Med Welt; 1975 Aug; 6(35):1499-502. PubMed ID: 1237073
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anti-platelet aggregation action and paradoxical effects of acetylsalicylic acid].
    Mocchi N; Sbalzarini G; Cantaluppi P
    Clin Ter; 1985 Jul; 114(1):37-41. PubMed ID: 4042578
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of platelet inhibitor therapy in coronary artery disease.
    Harbold NB
    Coll Works Cardiopulm Dis; 1982 May; 23():1-3. PubMed ID: 7047065
    [No Abstract]   [Full Text] [Related]  

  • 7. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy.
    Serebruany VL; Cummings CC; Malinin AI; Steinhubl SR; Gurbel PA
    Am Heart J; 2001 Oct; 142(4):611-6. PubMed ID: 11579350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
    Addad F; Chakroune T; Asma A; Abderazek F; Zohra D; Ghrissi I; Hassine M; Gamra H; Elalamy I
    Thromb Res; 2009 Feb; 123(4):640-3. PubMed ID: 18602138
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological inhibition of platelet aggregation in primary and secondary prevention of ischemic heart disease].
    Gryglik J
    Pol Tyg Lek; 1979 Mar; 34(13):509-11. PubMed ID: 375209
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
    Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet antiaggregants and arteriopathies].
    Cristol R
    J Mal Vasc; 1981; 6(3):237-41. PubMed ID: 7026714
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients].
    Addad F; Hassine M; Ben Farhat M; Abderrazak F; Chakroun T; Gamra H; Hamdi S; Betbout F; Samama M; Elalamy I
    Arch Mal Coeur Vaiss; 2005 Oct; 98(10):979-83. PubMed ID: 16294543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
    Garnier LF
    Ann Cardiol Angeiol (Paris); 1997 Oct; 46(8):507-12. PubMed ID: 9538362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease.
    Noble MI; Drake-Holland AJ
    Q J Med; 1994 Jan; 87(1):11-6. PubMed ID: 8140212
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.
    Lee PY; Chen WH; Ng W; Cheng X; Kwok JY; Tse HF; Lau CP
    Am J Med; 2005 Jul; 118(7):723-7. PubMed ID: 15989905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acetylsalicylic acid in coronary disease and cerebral ischemia (proceedings)].
    Fortschr Med; 1977 Dec; 95(47-48):2832. PubMed ID: 590910
    [No Abstract]   [Full Text] [Related]  

  • 20. [Acetosal and the heart].
    Verheugt FW
    Ned Tijdschr Geneeskd; 1984 Oct; 128(41):1951-3. PubMed ID: 6504178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.